FDA Warns Singapore Drugmaker Over Validation, Labeling Issues

The FDA hit drugmaker Opto-Pharm with a warning letter, citing a lack of written procedures for preventing contamination of sterile drug products, as well as problems with validation, testing and labeling.
Source: Drug Industry Daily